{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:43:51Z","timestamp":1790628231084,"version":"4.1.0"},"reference-count":188,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This work was funded by Fondazione IRCCS C\u00e0 Granda, Milan, Ricerca Corrente"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Significant progress has been made in the management of thyroid eye disease (TED), based on the elucidation of important pathogenic mechanisms. This has led to novel therapeutics validated in randomized clinical trials. Autoreactive antigens that elicit specific orbital immune reactions have not yet been identified, although it has been shown that fibrocytes, circulating stem cells that differentiate into fibroblasts, are expressing the thyroid-stimulating hormone receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R) and may be stimulated in the orbit by a cascade of inflammatory reactions inducing adipogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TED clinical assessment<\/jats:title>\n                    <jats:p>Moderate\u2013severe forms of TED are the target for immunosuppressive therapy. Improvement in the assessment of the active and progressive phase of disease is becoming compelling, as the outcome of a treatment depends on how early during the progressive phase the disease is treated. The clinical activity score may not always help define the right time for treating.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Therapy<\/jats:title>\n                    <jats:p>In 2020, teprotumumab, an anti-IGF-1 receptor blocker, has been approved by FDA for the treatment of TED. Since then, other drugs were studied or are under investigation and will seek regulatory approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Microbiome and TED<\/jats:title>\n                    <jats:p>A series of studies have investigated the role of microbiome in thyroid autoimmunity and TED more in detail, based on the observation that treatment with antibiotics may modify the disease phenotype in a murine model of TED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Artificial intelligence<\/jats:title>\n                    <jats:p>This approach is being studied for the assessment of TED, especially trying to standardize the use of orbital and facial images for improving the diagnosis of the disease in the early, progressive phase. In the future, these applications will allow the use of synthetic data, in addition to training on real patient images and data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0363","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:04:56Z","timestamp":1770048296000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":5,"title":["What has changed in thyroid eye disease in the last five years (2020\u20132025)"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-0367","authenticated-orcid":true,"given":"Mario","family":"Salvi","sequence":"first","affiliation":[{"name":"Graves\u2019 Orbitopathy Center, Fondazione IRCCs C\u00e0 Granda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Lancet Diabetes Endocrinolol","first-page":"600","article-title":"Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga WM","year":"2025","unstructured":"Wiersinga WM\n, \nEckstein AK\n & \n\u017darkovi\u0107 M\n\n. Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinolol 2025 13 600\u2013614. (https:\/\/doi.org\/10.1016\/s2213-8587(25)00066-x)"},{"key":"bib2","series-title":"Trans Am Ophthalmol Soc","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley GB","year":"1994","unstructured":"Bartley GB\n\n. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994 92 477\u2013588."},{"key":"bib3","series-title":"Front Endocrinol","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy","volume":"11","author":"Bartalena L","year":"2020","unstructured":"Bartalena L\n, \nPiantanida E\n, \nGallo D\n, et al.\n Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol 2020 11 615993. (https:\/\/doi.org\/10.3389\/fendo.2020.615993)"},{"key":"bib4","series-title":"Orphanet J Rare Dis","first-page":"72","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros P","year":"2017","unstructured":"Perros P\n, \nHeged\u00fcs L\n, \nBartalena L\n, et al.\n Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 2017 12 72. (https:\/\/doi.org\/10.1186\/s13023-017-0625-1)"},{"key":"bib5","series-title":"Nat Rev Dis Primers","first-page":"52","article-title":"Graves\u2019 disease","volume":"6","author":"Davies TF","year":"2020","unstructured":"Davies TF\n, \nAndersen S\n, \nLatif R\n, et al.\n Graves\u2019 disease. Nat Rev Dis Primers 2020 6 52. (https:\/\/doi.org\/10.1038\/s41572-020-0184-y)"},{"key":"bib6","series-title":"J Immunol","first-page":"6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard J","year":"2003","unstructured":"Pritchard J\n, \nHan R\n, \nHorst N\n, et al.\n Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003 170 6348\u20136354. (https:\/\/doi.org\/10.4049\/jimmunol.170.12.6348)"},{"key":"bib7","series-title":"Thyroid","first-page":"232","article-title":"Controversies surrounding IGF-I receptor involvement in thyroid-associated ophthalmopathy","volume":"35","author":"Smith TJ","year":"2025","unstructured":"Smith TJ\n\n. Controversies surrounding IGF-I receptor involvement in thyroid-associated ophthalmopathy. Thyroid 2025 35 232\u2013244. (https:\/\/doi.org\/10.1089\/thy.2024.0606)"},{"key":"bib8","series-title":"Sci Rep","first-page":"384","article-title":"Effects of linsitinib on M22 and IGF: 1-treated 3D spheroids of human orbital fibroblasts","volume":"15","author":"Hikage F","year":"2025","unstructured":"Hikage F\n, \nSuzuki M\n, \nSato T\n, et al.\n Effects of linsitinib on M22 and IGF: 1-treated 3D spheroids of human orbital fibroblasts. Sci Rep 2025 15 384. (https:\/\/doi.org\/10.1038\/s41598-024-83193-x)"},{"key":"bib9","series-title":"JCI Insight","article-title":"Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway","volume":"9","author":"Kim DW","year":"2024","unstructured":"Kim DW\n, \nKim S\n, \nHan J\n, et al.\n Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway. JCI Insight 2024 9 e182352. (https:\/\/doi.org\/10.1172\/jci.insight.182352)"},{"key":"bib10","series-title":"Endocrinology","article-title":"Mechanisms in thyroid eye disease: the TSH receptor interacts directly with the IGF-1 receptor","volume":"166","author":"Latif R","year":"2025","unstructured":"Latif R\n, \nMezei M\n & \nDavies TF\n\n. Mechanisms in thyroid eye disease: the TSH receptor interacts directly with the IGF-1 receptor. Endocrinology 2025 166 bqaf009. (https:\/\/doi.org\/10.1210\/endocr\/bqaf009)"},{"key":"bib11","series-title":"Cytokine","article-title":"Role of IL-6 in the commitment of T cell subsets","volume":"146","author":"Korn T","year":"2021","unstructured":"Korn T\n & \nHiltensperger M\n\n. Role of IL-6 in the commitment of T cell subsets. Cytokine 2021 146 155654. (https:\/\/doi.org\/10.1016\/j.cyto.2021.155654)"},{"key":"bib12","series-title":"Front Ophthalmol","article-title":"The role of IL-6 in thyroid eye disease: an update on emerging treatments","volume":"5","author":"Murdock J","year":"2025","unstructured":"Murdock J\n, \nNguyen J\n, \nHurtgen BJ\n, et al.\n The role of IL-6 in thyroid eye disease: an update on emerging treatments. Front Ophthalmol 2025 5 1544436. (https:\/\/doi.org\/10.3389\/fopht.2025.1544436). Erratum in:Front Ophthalmol. 2025 5 1641164."},{"key":"bib13","series-title":"Expert Rev Ophthalmol","first-page":"227","article-title":"Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside","volume":"9","author":"Rajaii F","year":"2014","unstructured":"Rajaii F\n, \nMcCoy A\n & \nSmith T\n\n. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside. Expert Rev Ophthalmol 2014 9 227\u2013234. (https:\/\/doi.org\/10.1586\/17469899.2014.917960)"},{"key":"bib14","series-title":"Autoimmunity","first-page":"91","article-title":"High circulating IL-6 level in Graves\u2019 ophthalmopathy","volume":"25","author":"Molnar I","year":"1997","unstructured":"Molnar I\n & \nBalazs C\n\n. High circulating IL-6 level in Graves\u2019 ophthalmopathy. Autoimmunity 1997 25 91\u201396. (https:\/\/doi.org\/10.3109\/08916939708996275)"},{"key":"bib15","series-title":"Clin Exp Immunol","first-page":"453","article-title":"Both Th1- and Th2-derived cytokines in serum are elevated in Graves\u2019 ophthalmopathy","volume":"121","author":"Wakelkamp IM","year":"2001","unstructured":"Wakelkamp IM\n, \nGerding MN\n, \nVan Der Meer JW\n, et al.\n Both Th1- and Th2-derived cytokines in serum are elevated in Graves\u2019 ophthalmopathy. Clin Exp Immunol 2001 121 453\u2013457. (https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01335.x)"},{"key":"bib16","series-title":"Endocr Res","first-page":"89","article-title":"CD8 + CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves\u2019 orbitopathy and correlate with disease activity","volume":"37","author":"Slowik M","year":"2012","unstructured":"Slowik M\n, \nUrbaniak-Kujda D\n, \nBohdanowicz-Pawlak A\n, et al.\n CD8 + CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves\u2019 orbitopathy and correlate with disease activity. Endocr Res 2012 37 89\u201395. (https:\/\/doi.org\/10.3109\/07435800.2011.635622)"},{"key":"bib17","series-title":"J Clin Endocrinol Metab","first-page":"2976","article-title":"Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease","volume":"81","author":"Salvi M","year":"1996","unstructured":"Salvi M\n, \nGirasole G\n, \nPedrazzoni M\n, et al.\n Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease. J Clin Endocrinol Metab 1996 81 2976\u20132979. (https:\/\/doi.org\/10.1210\/jcem.81.8.8768861)"},{"key":"bib18","series-title":"Eur J Endocrinol","first-page":"197","article-title":"Serum concentrations of proinflammatory cytokines in Graves\u2019 disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking","volume":"143","author":"Salvi M","year":"2000","unstructured":"Salvi M\n, \nPedrazzoni M\n, \nGirasole G\n, et al.\n Serum concentrations of proinflammatory cytokines in Graves\u2019 disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000 143 197\u2013202. (https:\/\/doi.org\/10.1530\/eje.0.1430197)"},{"key":"bib19","series-title":"Thyroid","first-page":"59","article-title":"A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves\u2019 orbital preadipocyte fibroblasts","volume":"20","author":"Kumar S","year":"2010","unstructured":"Kumar S\n, \nSchiefer R\n, \nCoenen MJ\n, et al.\n A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves\u2019 orbital preadipocyte fibroblasts. Thyroid 2010 20 59\u201365. (https:\/\/doi.org\/10.1089\/thy.2009.0278)"},{"key":"bib20","series-title":"Sci Rep","article-title":"Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy","volume":"8","author":"Kishazi E","year":"2018","unstructured":"Kishazi E\n, \nDor M\n, \nEperon S\n, et al.\n Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy. Sci Rep 2018 8 10792. (https:\/\/doi.org\/10.1038\/s41598-018-29113-2)"},{"key":"bib21","series-title":"Thyroid","first-page":"338","article-title":"M1-like macrophages modulate fibrosis and inflammation of orbital fibroblasts in Graves\u2019 orbitopathy: potential relevance to soluble Interleukin-6 receptor","volume":"33","author":"Lu Y","year":"2023","unstructured":"Lu Y\n, \nWang Y\n, \nWang Y\n, et al.\n M1-like macrophages modulate fibrosis and inflammation of orbital fibroblasts in Graves\u2019 orbitopathy: potential relevance to soluble Interleukin-6 receptor. Thyroid 2023 33 338\u2013350. (https:\/\/doi.org\/10.1089\/thy.2022.0254)"},{"key":"bib22","series-title":"J Clin Endocrinol Metab","first-page":"1194","article-title":"Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy","volume":"85","author":"Hiromatsu Y","year":"2000","unstructured":"Hiromatsu Y\n, \nYang D\n, \nBednarczuk T\n, et al.\n Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000 85 1194\u20131199. (https:\/\/doi.org\/10.1210\/jcem.85.3.6433)"},{"key":"bib23","series-title":"Br J Ophthalmol","first-page":"639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits MP","year":"1989","unstructured":"Mourits MP\n, \nKoornneef L\n, \nWiersinga WM\n, et al.\n Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol 1989 73 639\u2013644. (https:\/\/doi.org\/10.1136\/bjo.73.8.639)"},{"key":"bib24","series-title":"Clin Endocrinol","first-page":"9","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourits MP","year":"1997","unstructured":"Mourits MP\n, \nPrummel MF\n, \nWiersinga WM\n, et al\n. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol 1997 47 9\u201314. (https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2331047.x). Erratum in: Clin Endocrinol 1997 47 632."},{"key":"bib25","series-title":"Am J Ophthalmol","first-page":"94","article-title":"Inter-observer variability of clinical activity score: assessments in patients with thyroid eye disease","volume":"252","author":"Perros P","year":"2023","unstructured":"Perros P\n, \n\u017darkovi\u0107 M\n, \nPearce SH\n, et al.\n Inter-observer variability of clinical activity score: assessments in patients with thyroid eye disease. Am J Ophthalmol 2023 252 94\u2013100. (https:\/\/doi.org\/10.1016\/j.ajo.2023.03.027)"},{"key":"bib26","series-title":"Horm Metab Res","first-page":"779","article-title":"Medical treatment of Graves\u2019 orbitopathy","volume":"47","author":"Salvi M","year":"2015","unstructured":"Salvi M\n & \nCampi I\n\n. Medical treatment of Graves\u2019 orbitopathy. Horm Metab Res 2015 47 779\u2013788. (https:\/\/doi.org\/10.1055\/s-0035-1554721)"},{"key":"bib27","series-title":"US Food & Drug Administration","article-title":"Drug trials snapshots: Summary report","year":"21 Feb 2021","unstructured":"Drug trials snapshots: Summary report. US Food & Drug Administration 21 Feb 2021. (https:\/\/www.fda.gov\/media\/145718\/download)"},{"key":"bib28","series-title":"Ophthalmology","first-page":"1092","article-title":"A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves\u2019 orbitopathy","volume":"120","author":"Campi I","year":"2013","unstructured":"Campi I\n, \nVannucchi GM\n, \nMinetti AM\n, et al.\n A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves\u2019 orbitopathy. Ophthalmology 2013 120 1092\u20131098. (https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.041)"},{"key":"bib29","series-title":"Sci Rep","article-title":"Measurement of proptosis using computed tomography based three-dimensional reconstruction software in patients with Graves\u2019 orbitopathy","volume":"10","author":"Huh J","year":"2020","unstructured":"Huh J\n, \nPark SJ\n & \nLee JK\n\n. Measurement of proptosis using computed tomography based three-dimensional reconstruction software in patients with Graves\u2019 orbitopathy. Sci Rep 2020 10 14554. (https:\/\/doi.org\/10.1038\/s41598-020-71098-4)"},{"key":"bib30","series-title":"Eur J Endocrinol","first-page":"273","article-title":"Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena L","year":"2008","unstructured":"Bartalena L\n, \nBaldeschi L\n, \nDickinson A\n, et al.\n Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008 158 273\u2013285. (https:\/\/doi.org\/10.1530\/eje-07-0666)"},{"key":"bib31","series-title":"Thyroid","first-page":"539","article-title":"The measurement of change in Graves\u2019 ophthalmopathy","volume":"8","author":"Gorman CA","year":"1998","unstructured":"Gorman CA\n\n. The measurement of change in Graves\u2019 ophthalmopathy. Thyroid 1998 8 539\u2013543. (https:\/\/doi.org\/10.1089\/thy.1998.8.539)"},{"key":"bib32","series-title":"Ophthalmology","first-page":"382","article-title":"Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study","volume":"119","author":"Dolman PJ","year":"2012","unstructured":"Dolman PJ\n, \nCahill K\n, \nCzyz CN\n, et al.\n Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. Ophthalmology 2012 119 382\u2013389. (https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.011)"},{"key":"bib33","series-title":"Thyroid","first-page":"280","article-title":"Quantification of global ocular motility impairment in Graves\u2019 orbitopathy by measuring eye muscle ductions","volume":"31","author":"Campi I","year":"2021","unstructured":"Campi I\n, \nCurr\u00f2 N\n, \nVannucchi G\n, et al.\n Quantification of global ocular motility impairment in Graves\u2019 orbitopathy by measuring eye muscle ductions. Thyroid 2021 31 280\u2013287. (https:\/\/doi.org\/10.1089\/thy.2020.0165)"},{"key":"bib34","series-title":"J Clin Endocrinol Metab","first-page":"4454","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena L","year":"2012","unstructured":"Bartalena L\n, \nKrassas GE\n, \nWiersinga W\n, et al.\n Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab 2012 97 4454\u20134463. (https:\/\/doi.org\/10.1210\/jc.2012-2389)"},{"key":"bib35","series-title":"Eur J Endocrinol","first-page":"R101","article-title":"Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy \u2013 lessons from randomized control trials","volume":"176","author":"Stan MN","year":"2017","unstructured":"Stan MN\n & \nSalvi M\n\n. Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy \u2013 lessons from randomized control trials. Eur J Endocrinol 2017 176 R101\u2013R109. (https:\/\/doi.org\/10.1530\/eje-16-0552)"},{"key":"bib36","series-title":"Lancet Diabetes Endocrinol","first-page":"733","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla G","year":"2021","unstructured":"Lanzolla G\n, \nSabini E\n, \nLeo M\n, et al.\n Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol 2021 9 733\u2013742. (https:\/\/doi.org\/10.1016\/s2213-8587(21)00238-2)"},{"key":"bib37","series-title":"Lancet Diabetes Endocrinol","first-page":"287","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly GJ","year":"2018","unstructured":"Kahaly GJ\n, \nRiedl M\n, \nK\u00f6nig J\n, et al.\n Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 2018 6 287\u2013298. (https:\/\/doi.org\/10.1016\/s2213-8587(18)30020-2)"},{"key":"bib38","series-title":"Clin Endocrinol","first-page":"391","article-title":"Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee CB","year":"2001","unstructured":"Terwee CB\n, \nDekker FW\n, \nMourits MP\n, et al.\n Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol 2001 54 391\u2013398. (https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01241.x)"},{"key":"bib39","series-title":"Eur J Endocrinol","first-page":"G43","article-title":"The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena L","year":"2021","unstructured":"Bartalena L\n, \nKahaly GJ\n, \nBaldeschi L\n, et al.\n The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 2021 185 G43\u2013G67. (https:\/\/doi.org\/10.1530\/eje-21-0479)"},{"key":"bib40","series-title":"Eur Thyroid J","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch HB","year":"2022","unstructured":"Burch HB\n, \nPerros P\n, \nBednarczuk T\n, et al.\n Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J 2022 11 e220189. (https:\/\/doi.org\/10.1530\/etj-22-0189)"},{"key":"bib41","series-title":"N Engl J Med","first-page":"1748","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith TJ","year":"2017","unstructured":"Smith TJ\n, \nKahaly GJ\n, \nEzra DG\n, et al.\n Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 2017 376 1748\u20131761. (https:\/\/doi.org\/10.1056\/nejmoa1614949)"},{"key":"bib42","series-title":"N Engl J Med","first-page":"341","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas RS","year":"2020","unstructured":"Douglas RS\n, \nKahaly GJ\n, \nPatel A\n, et al.\n Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020 382 341\u2013352. (https:\/\/doi.org\/10.1056\/nejmoa1910434)"},{"key":"bib43","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"162","article-title":"Treatment of active corticosteroid-resistant Graves\u2019 orbitopathy","volume":"30","author":"Perez-Moreiras JV","year":"2014","unstructured":"Perez-Moreiras JV\n, \nAlvarez-Lopez A\n & \nGomez EC\n\n. Treatment of active corticosteroid-resistant Graves\u2019 orbitopathy. Ophthalmic Plast Reconstr Surg 2014 30 162\u2013167. (https:\/\/doi.org\/10.1097\/iop.0000000000000037)"},{"key":"bib44","series-title":"Am J Ophthalmol","first-page":"181","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras JV","year":"2018","unstructured":"Perez-Moreiras JV\n, \nGomez-Reino JJ\n, \nManeiro JR\n, et al.\n Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 2018 195 181\u2013190. (https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038)"},{"key":"bib45","series-title":"J Clin Endocrinol Metab","first-page":"422","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi M","year":"2015","unstructured":"Salvi M\n, \nVannucchi G\n, \nCurr\u00f2 N\n, et al.\n Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015 100 422\u2013431. (https:\/\/doi.org\/10.1210\/jc.2014-3014)"},{"key":"bib46","series-title":"Thyroid","first-page":"821","article-title":"Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy","volume":"31","author":"Vannucchi G","year":"2021","unstructured":"Vannucchi G\n, \nCampi I\n, \nCovelli D\n, et al.\n Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid 2021 31 821\u2013828. (https:\/\/doi.org\/10.1089\/thy.2020.0269)"},{"key":"bib47","series-title":"Thyroid","first-page":"1181","article-title":"Future research in Graves\u2019 orbitopathy: from priority setting to trial design through patient and public involvement","volume":"25","author":"Perros P","year":"2015","unstructured":"Perros P\n, \nDayan CM\n, \nDickinson AJ\n, et al.\n Future research in Graves\u2019 orbitopathy: from priority setting to trial design through patient and public involvement. Thyroid 2015 25 1181\u20131184. (https:\/\/doi.org\/10.1089\/thy.2015.0222)"},{"key":"bib48","series-title":"Front Endocrinol","article-title":"How patients experience thyroid eye disease","volume":"14","author":"Smith TJ","year":"2023","unstructured":"Smith TJ\n, \nHeged\u00fcs L\n, \nLesser I\n, et al.\n How patients experience thyroid eye disease. Front Endocrinol 2023 14 1283374. (https:\/\/doi.org\/10.3389\/fendo.2023.1283374)"},{"key":"bib49","series-title":"Lancet Reg Health West Pac","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu Y","year":"2025","unstructured":"Hiromatsu Y\n, \nIshikawa E\n, \nKozaki A\n, et al.\n A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. Lancet Reg Health West Pac 2025 55 101464. (https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101464). Erratum in: Lancet Reg Health West Pac. 2025 60 101607."},{"key":"bib50","article-title":"First treatment against severe thyroid eye disease","author":"European Medicines Agency","year":"25 Apr 2025","unstructured":"European Medicines Agency\n. First treatment against severe thyroid eye disease. 25 Apr 2025. (https:\/\/www.ema.europa.eu\/en\/news\/first-treatment-against-severe-thyroid-eye-disease)"},{"key":"bib51","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"583","article-title":"Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population","volume":"37","author":"Diniz SB","year":"2021","unstructured":"Diniz SB\n, \nCohen LM\n, \nRoelofs KA\n, et al.\n Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg 2021 37 583\u2013591. (https:\/\/doi.org\/10.1097\/iop.0000000000001959)"},{"key":"bib52","series-title":"Thyroid","first-page":"1202","article-title":"Teprotumumab treatment in patients with steroid and surgery-resistant dysthyroid optic neuropathy: a case series","volume":"35","author":"Carretti AL","year":"2025","unstructured":"Carretti AL\n, \nKielwasser G\n, \nBorson-Chazot F\n, et al.\n Teprotumumab treatment in patients with steroid and surgery-resistant dysthyroid optic neuropathy: a case series. Thyroid 2025 35 1202\u20131207. (https:\/\/doi.org\/10.1177\/10507256251372194)"},{"key":"bib53","series-title":"J Neuro Ophthalmol","first-page":"74","article-title":"Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy","volume":"44","author":"Tamhankar MA","year":"2024","unstructured":"Tamhankar MA\n, \nPradeep T\n, \nChen Y\n, et al.\n Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy. J Neuro Ophthalmol 2024 44 74\u201379. (https:\/\/doi.org\/10.1097\/wno.0000000000001994)"},{"key":"bib54","series-title":"Ophthalmology","first-page":"438","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas RS","year":"2022","unstructured":"Douglas RS\n, \nKahaly GJ\n, \nUgradar S\n, et al.\n Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology 2022 129 438\u2013449. (https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017)"},{"key":"bib55","series-title":"J Clin Endocrinol Metab","first-page":"25","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas RS","year":"2023","unstructured":"Douglas RS\n, \nCouch S\n, \nWester ST\n, et al.\n Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab 2023 109 25\u201335. (https:\/\/doi.org\/10.1210\/clinem\/dgad637)"},{"key":"bib56","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"187","article-title":"Proptosis regression after teprotumumab treatment for thyroid eye disease","volume":"40","author":"Rosenblatt TR","year":"2024","unstructured":"Rosenblatt TR\n, \nChiou CA\n, \nYoon MK\n, et al.\n Proptosis regression after teprotumumab treatment for thyroid eye disease. Ophthalmic Plast Reconstr Surg 2024 40 187\u2013191. (https:\/\/doi.org\/10.1097\/iop.0000000000002531)"},{"key":"bib57","series-title":"Am J Ophthalmol","first-page":"152","article-title":"Reactivation after teprotumumab treatment for active thyroid eye disease","volume":"263","author":"Hwang CJ","year":"2024","unstructured":"Hwang CJ\n, \nRebollo NP\n, \nMechels KB\n, et al.\n Reactivation after teprotumumab treatment for active thyroid eye disease. Am J Ophthalmol 2024 263 152\u2013159. (https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001)"},{"key":"bib58","series-title":"Ophthalmology","first-page":"815","article-title":"Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials","volume":"131","author":"Smith TJ","year":"2024","unstructured":"Smith TJ\n, \nCavida D\n, \nHsu K\n, et al.\n Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials. Ophthalmology 2024 131 815\u2013826. (https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.023)"},{"key":"bib59","series-title":"Ophthalmology","first-page":"30","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen JA","year":"2024","unstructured":"Keen JA\n, \nCorrea T\n, \nPham C\n, et al.\n Frequency and patterns of hearing dysfunction in patients treated with teprotumumab. Ophthalmology 2024 131 30\u201336. (https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.001)"},{"key":"bib60","series-title":"J Clin Endocrinol Metab","first-page":"811","article-title":"Assessment of hearing dysfunction in patients with Graves\u2019 disease and thyroid eye disease without or with teprotumumab","volume":"110","author":"Smith TJ","year":"2025","unstructured":"Smith TJ\n, \nHolt RJ\n, \nFu Q\n, et al.\n Assessment of hearing dysfunction in patients with Graves\u2019 disease and thyroid eye disease without or with teprotumumab. J Clin Endocrinol Metab 2025 110 811\u2013819. (https:\/\/doi.org\/10.1210\/clinem\/dgae560)"},{"key":"bib61","series-title":"JAMA Ophthalmol","article-title":"IGF-1R inhibitor IBI311 for the treatment of active thyroid eye disease in Chinese patients: the RESTORE-1 randomized clinical trial","volume":"9","author":"Zhang H","year":"2025","unstructured":"Zhang H\n, \nSun J\n, \nLi Y\n, et al.\n IGF-1R inhibitor IBI311 for the treatment of active thyroid eye disease in Chinese patients: the RESTORE-1 randomized clinical trial. JAMA Ophthalmol 2025 9 e253350. (https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.3350)"},{"key":"bib62","series-title":"Front Endocrinol","article-title":"Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease","volume":"14","author":"Gulbins A","year":"2023","unstructured":"Gulbins A\n, \nHorstmann M\n, \nDaser A\n, et al.\n Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Front Endocrinol 2023 14 1211473. (https:\/\/doi.org\/10.3389\/fendo.2023.1211473)"},{"key":"bib63","series-title":"BioDrugs","first-page":"61","article-title":"Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned?","volume":"38","author":"Avci AB","year":"2024","unstructured":"Avci AB\n, \nFeist E\n & \nBurmester GR\n\n. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned? BioDrugs 2024 38 61\u201371. (https:\/\/doi.org\/10.1007\/s40259-023-00634-1)"},{"key":"bib64","series-title":"RMD Open","article-title":"A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases","volume":"8","author":"Kastrati K","year":"2022","unstructured":"Kastrati K\n, \nAletaha D\n, \nBurmester GR\n, et al.\n A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 2022 8 e002359. (https:\/\/doi.org\/10.1136\/rmdopen-2022-002359)"},{"key":"bib65","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"367","article-title":"Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review","volume":"40","author":"Duarte AF","year":"2024","unstructured":"Duarte AF\n, \nXavier NF\n, \nSales Sanz M\n, et al.\n Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review. Ophthalmic Plast Reconstr Surg 2024 40 367\u2013373. (https:\/\/doi.org\/10.1097\/iop.0000000000002573)"},{"key":"bib66","series-title":"Clin Endocrinol","first-page":"363","article-title":"Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab","volume":"97","author":"Moi L","year":"2022","unstructured":"Moi L\n, \nHamedani M\n & \nRibi C\n\n. Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab. Clin Endocrinol 2022 97 363\u2013370. (https:\/\/doi.org\/10.1111\/cen.14655)"},{"key":"bib67","series-title":"Int Ophthalmol","first-page":"179","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study","volume":"44","author":"Lee C","year":"2024","unstructured":"Lee C\n, \nPark JW\n, \nKim YD\n, et al.\n Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study. Int Ophthalmol 2024 44 179. (https:\/\/doi.org\/10.1007\/s10792-024-03117-6)"},{"key":"bib68","series-title":"J Clin Endocrinol Metab","first-page":"e886","article-title":"The efficacy and safety of intravenous tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and single-arm meta-analysis","volume":"110","author":"Sun A","year":"2025","unstructured":"Sun A\n, \nWang X\n, \nQu J\n, et al.\n The efficacy and safety of intravenous tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and single-arm meta-analysis. J Clin Endocrinol Metab 2025 110 e886\u2013e896. (https:\/\/doi.org\/10.1210\/clinem\/dgae711)"},{"key":"bib69","series-title":"Front Endocrinol","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study","volume":"14","author":"Boutzios G","year":"2023","unstructured":"Boutzios G\n, \nChatzi S\n, \nGoules AV\n, et al.\n Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study. Front Endocrinol 2023 14 1186105. (https:\/\/doi.org\/10.3389\/fendo.2023.1186105)"},{"key":"bib70","series-title":"Taiwan J Ophthalmol","first-page":"39","article-title":"Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers","volume":"12","author":"Stevens SM","year":"2022","unstructured":"Stevens SM\n, \nPirakitikulr N\n & \nLee BW\n\n. Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers. Taiwan J Ophthalmol 2022 12 39\u201343. (https:\/\/doi.org\/10.4103\/tjo.tjo_59_21)"},{"key":"bib71","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"e64","article-title":"Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery","volume":"35","author":"Copperman T","year":"2019","unstructured":"Copperman T\n, \nIdowu OO\n, \nKersten RC\n, et al.\n Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast Reconstr Surg 2019 35 e64\u2013e66. (https:\/\/doi.org\/10.1097\/iop.0000000000001346)"},{"key":"bib72","series-title":"Lancet Neurol","first-page":"402","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee A","year":"2020","unstructured":"Traboulsee A\n, \nGreenberg BM\n, \nBennett JL\n, et al.\n Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020 19 402\u2013412. (https:\/\/doi.org\/10.1016\/s1474-4422(20)30078-8)"},{"key":"bib73","series-title":"N Engl J Med","first-page":"2114","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura T","year":"2019","unstructured":"Yamamura T\n, \nKleiter I\n, \nFujihara K\n, et al.\n Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019 381 2114\u20132124. (https:\/\/doi.org\/10.1056\/nejmoa1901747)"},{"key":"bib74","series-title":"Mol Immunol","first-page":"131","article-title":"Targeting FcRn for the modulation of antibody dynamics","volume":"67","author":"Ward ES","year":"2015","unstructured":"Ward ES\n, \nDevanaboyina SC\n & \nOber RJ\n\n. Targeting FcRn for the modulation of antibody dynamics. Mol Immunol 2015 67 131\u2013141. (https:\/\/doi.org\/10.1016\/j.molimm.2015.02.007)"},{"key":"bib75","series-title":"Immunol Rev","first-page":"253","article-title":"The multiple facets of FcRn in immunity","volume":"268","author":"Stapleton NM","year":"2015","unstructured":"Stapleton NM\n, \nEinarsd\u00f3ttir HK\n, \nStemerding AM\n, et al.\n The multiple facets of FcRn in immunity. Immunol Rev 2015 268 253\u2013268. (https:\/\/doi.org\/10.1111\/imr.12331)"},{"key":"bib76","series-title":"Adv Drug Deliver Rev","first-page":"109","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky JT","year":"2015","unstructured":"Sockolosky JT\n & \nSzoka FC\n\n. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliver Rev 2015 91 109\u2013124. (https:\/\/doi.org\/10.1016\/j.addr.2015.02.005)"},{"key":"bib77","series-title":"J Clin Endocrinol Metab","first-page":"3122","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly GJ","year":"2023","unstructured":"Kahaly GJ\n, \nDolman PJ\n, \nWolf J\n, et al.\n Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab 2023 108 3122\u20133134. (https:\/\/doi.org\/10.1210\/clinem\/dgad381)"},{"key":"bib78","series-title":"J Endocr Soc","article-title":"OR31-08 the FcRn inhibitor batoclimab rapidly normalizes thyroid function and improves clinical outcomes in Graves\u2019 disease","volume":"9","author":"Kahaly GJ","year":"2025","unstructured":"Kahaly GJ\n, \nWolf J\n, \nGanz AL\n, et al.\n OR31-08 the FcRn inhibitor batoclimab rapidly normalizes thyroid function and improves clinical outcomes in Graves\u2019 disease. J Endocr Soc 2025 9 bvaf1492241. (https:\/\/doi.org\/10.1210\/jendso\/bvaf149.2241)"},{"key":"bib79","series-title":"J Clin Endocrinol Metab","article-title":"Secukinumab in moderate-to-severe Graves\u2019 orbitopathy: a randomized, double-blind, placebo-controlled, multicenter study","volume":"9","author":"Wolf J","year":"2025","unstructured":"Wolf J\n, \nLorenz K\n, \nOthman AE\n, et al.\n Secukinumab in moderate-to-severe Graves\u2019 orbitopathy: a randomized, double-blind, placebo-controlled, multicenter study. J Clin Endocrinol Metab 2025 9 dgaf655. (https:\/\/doi.org\/10.1210\/clinem\/dgaf655)"},{"key":"bib80","series-title":"Nature","first-page":"1282","article-title":"Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43","volume":"461","author":"Maslowski KM","year":"2009","unstructured":"Maslowski KM\n, \nVieira AT\n, \nNg A\n, et al.\n Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009 461 1282\u20131286. (https:\/\/doi.org\/10.1038\/nature08530)"},{"key":"bib81","series-title":"Compar Med","first-page":"336","article-title":"Variation in the gut microbiota of laboratory mice is related to both genetic and environmental factors","volume":"60","author":"Hufeldt MR","year":"2010","unstructured":"Hufeldt MR\n, \nNielsen DS\n, \nVogensen FK\n, et al.\n Variation in the gut microbiota of laboratory mice is related to both genetic and environmental factors. Compar Med 2010 60 336\u2013347."},{"key":"bib82","series-title":"Microbiome","first-page":"97","article-title":"Gut microbiota in experimental murine model of Graves\u2019 orbitopathy established in different environments may modulate clinical presentation of disease","volume":"6","author":"Masetti G","year":"2018","unstructured":"Masetti G\n, \nMoshkelgosha S\n, \nK\u00f6hling HL\n, et al.\n Gut microbiota in experimental murine model of Graves\u2019 orbitopathy established in different environments may modulate clinical presentation of disease. Microbiome 2018 6 97. (https:\/\/doi.org\/10.1186\/s40168-018-0478-4)"},{"key":"bib83","series-title":"Microbiome","first-page":"45","article-title":"Modulating gut microbiota in a mouse model of Graves\u2019 orbitopathy and its impact on induced disease","volume":"9","author":"Moshkelgosha S","year":"2021","unstructured":"Moshkelgosha S\n, \nVerhasselt HL\n, \nMasetti G\n, et al.\n Modulating gut microbiota in a mouse model of Graves\u2019 orbitopathy and its impact on induced disease. Microbiome 2021 9 45. (https:\/\/doi.org\/10.1186\/s40168-020-00952-4)"},{"key":"bib84","series-title":"Front Endocrinol","article-title":"Association between gut microbiota and autoimmune thyroid disease: a systematic review and meta-analysis","volume":"12","author":"Gong B","year":"2021","unstructured":"Gong B\n, \nWang C\n, \nMeng F\n, et al.\n Association between gut microbiota and autoimmune thyroid disease: a systematic review and meta-analysis. Front Endocrinol 2021 12 774362. (https:\/\/doi.org\/10.3389\/fendo.2021.774362)"},{"key":"bib85","series-title":"Nat Rev Endocrinol","first-page":"511","article-title":"The relationship between the gut microbiota and thyroid disorders","volume":"20","author":"Ludgate ME","year":"2024","unstructured":"Ludgate ME\n, \nMasetti G\n & \nSoares P\n\n. The relationship between the gut microbiota and thyroid disorders. Nat Rev Endocrinol 2024 20 511\u2013525. (https:\/\/doi.org\/10.1038\/s41574-024-01003-w)"},{"key":"bib86","series-title":"J Clin Endocrinol Metab","first-page":"2065","article-title":"Gut microbiome associated with Graves disease and Graves orbitopathy: the INDIGO multicenter European Study","volume":"108","author":"Biscarini F","year":"2023","unstructured":"Biscarini F\n, \nMasetti G\n, \nMuller I\n, et al.\n Gut microbiome associated with Graves disease and Graves orbitopathy: the INDIGO multicenter European Study. J Clin Endocrinol Metab 2023 108 2065\u20132077. (https:\/\/doi.org\/10.1210\/clinem\/dgad030). Erratum in: J Clin Endocrinol Metab. 2024 109 e880."},{"key":"bib87","series-title":"Endocrine","first-page":"689","article-title":"Large language models: unlocking new potential in patient education for thyroid eye disease","volume":"90","author":"Gao Y","year":"2025","unstructured":"Gao Y\n, \nXu Q\n, \nZhang O\n, et al.\n Large language models: unlocking new potential in patient education for thyroid eye disease. Endocrine 2025 90 689\u2013698. (https:\/\/doi.org\/10.1007\/s12020-025-04339-z)"},{"key":"bib88","series-title":"Front Endocrinol","article-title":"Application of artificial intelligence in the assessment of thyroid eye disease (TED) \u2013 a scoping review","volume":"14","author":"Chng CL","year":"2023","unstructured":"Chng CL\n, \nZheng K\n, \nKwee AK\n, et al.\n Application of artificial intelligence in the assessment of thyroid eye disease (TED) \u2013 a scoping review. Front Endocrinol 2023 14 1300196. (https:\/\/doi.org\/10.3389\/fendo.2023.1300196)"},{"key":"bib89","series-title":"Ophthalmology","first-page":"1703","article-title":"Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network","volume":"109","author":"Salvi M","year":"2002","unstructured":"Salvi M\n, \nDazzi D\n, \nPellistri I\n, et al.\n Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network. Ophthalmology 2002 109 1703\u20131708. (https:\/\/doi.org\/10.1016\/s0161-6420(02)01127-2)"},{"key":"bib90","series-title":"Surv Ophthalmol","first-page":"142","article-title":"Artificial intelligence in thyroid eye disease imaging: a systematic review","volume":"71","author":"Zhang H","year":"2026","unstructured":"Zhang H\n, \nLi Z\n, \nChan HC\n, et al.\n Artificial intelligence in thyroid eye disease imaging: a systematic review. Surv Ophthalmol 2026 71 142\u2013157. (https:\/\/doi.org\/10.1016\/j.survophthal.2025.07.008)"},{"key":"bib91","series-title":"Ophthalmol Sci","article-title":"Deep learning-driven exophthalmometry through facial photographs in thyroid eye disease","volume":"5","author":"Park J","year":"2025","unstructured":"Park J\n, \nYoon JS\n, \nKim N\n, et al.\n Deep learning-driven exophthalmometry through facial photographs in thyroid eye disease. Ophthalmol Sci 2025 5 100791. (https:\/\/doi.org\/10.1016\/j.xops.2025.100791)"},{"key":"bib92","series-title":"BMJ Open Ophthalmol","article-title":"AI-based assessment of clinical activity score and detection of active thyroid eye disease using facial images: validation of Glandy CAS","volume":"10","author":"Shin K","year":"2025","unstructured":"Shin K\n, \nYoon JS\n, \nKim J\n, et al.\n AI-based assessment of clinical activity score and detection of active thyroid eye disease using facial images: validation of Glandy CAS. BMJ Open Ophthalmol 2025 10 e002264. (https:\/\/doi.org\/10.1136\/bmjophth-2025-002264)"},{"key":"bib93","series-title":"BMC Ophthalmol","first-page":"162","article-title":"Comparative analysis of deep learning architectures for thyroid eye disease detection using facial photographs","volume":"25","author":"Aghajani A","year":"2025","unstructured":"Aghajani A\n, \nRajabi MT\n, \nRafizadeh SM\n, et al.\n Comparative analysis of deep learning architectures for thyroid eye disease detection using facial photographs. BMC Ophthalmol 2025 25 162. (https:\/\/doi.org\/10.1186\/s12886-025-03988-y)"},{"key":"bib94","series-title":"Thyroid","first-page":"744","article-title":"A preliminary evaluation of the diagnostic performance of a smartphone-based machine learning-assisted system for evaluation of clinical activity score in digital images of thyroid-associated orbitopathy","volume":"34","author":"Shin K","year":"2024","unstructured":"Shin K\n, \nChoung H\n, \nLee MJ\n, et al.\n A preliminary evaluation of the diagnostic performance of a smartphone-based machine learning-assisted system for evaluation of clinical activity score in digital images of thyroid-associated orbitopathy. Thyroid 2024 34 744\u2013752. (https:\/\/doi.org\/10.1089\/thy.2023.0621)"},{"key":"bib1","series-title":"Lancet Diabetes Endocrinolol","first-page":"600","article-title":"Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga WM","year":"2025","unstructured":"Wiersinga WM\n, \nEckstein AK\n & \n\u017darkovi\u0107 M\n\n. Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinolol 2025 13 600\u2013614. (https:\/\/doi.org\/10.1016\/s2213-8587(25)00066-x)"},{"key":"bib2","series-title":"Trans Am Ophthalmol Soc","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley GB","year":"1994","unstructured":"Bartley GB\n\n. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994 92 477\u2013588."},{"key":"bib3","series-title":"Front Endocrinol","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy","volume":"11","author":"Bartalena L","year":"2020","unstructured":"Bartalena L\n, \nPiantanida E\n, \nGallo D\n, et al.\n Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol 2020 11 615993. (https:\/\/doi.org\/10.3389\/fendo.2020.615993)"},{"key":"bib4","series-title":"Orphanet J Rare Dis","first-page":"72","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros P","year":"2017","unstructured":"Perros P\n, \nHeged\u00fcs L\n, \nBartalena L\n, et al.\n Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 2017 12 72. (https:\/\/doi.org\/10.1186\/s13023-017-0625-1)"},{"key":"bib5","series-title":"Nat Rev Dis Primers","first-page":"52","article-title":"Graves\u2019 disease","volume":"6","author":"Davies TF","year":"2020","unstructured":"Davies TF\n, \nAndersen S\n, \nLatif R\n, et al.\n Graves\u2019 disease. Nat Rev Dis Primers 2020 6 52. (https:\/\/doi.org\/10.1038\/s41572-020-0184-y)"},{"key":"bib6","series-title":"J Immunol","first-page":"6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard J","year":"2003","unstructured":"Pritchard J\n, \nHan R\n, \nHorst N\n, et al.\n Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003 170 6348\u20136354. (https:\/\/doi.org\/10.4049\/jimmunol.170.12.6348)"},{"key":"bib7","series-title":"Thyroid","first-page":"232","article-title":"Controversies surrounding IGF-I receptor involvement in thyroid-associated ophthalmopathy","volume":"35","author":"Smith TJ","year":"2025","unstructured":"Smith TJ\n\n. Controversies surrounding IGF-I receptor involvement in thyroid-associated ophthalmopathy. Thyroid 2025 35 232\u2013244. (https:\/\/doi.org\/10.1089\/thy.2024.0606)"},{"key":"bib8","series-title":"Sci Rep","first-page":"384","article-title":"Effects of linsitinib on M22 and IGF: 1-treated 3D spheroids of human orbital fibroblasts","volume":"15","author":"Hikage F","year":"2025","unstructured":"Hikage F\n, \nSuzuki M\n, \nSato T\n, et al.\n Effects of linsitinib on M22 and IGF: 1-treated 3D spheroids of human orbital fibroblasts. Sci Rep 2025 15 384. (https:\/\/doi.org\/10.1038\/s41598-024-83193-x)"},{"key":"bib9","series-title":"JCI Insight","article-title":"Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway","volume":"9","author":"Kim DW","year":"2024","unstructured":"Kim DW\n, \nKim S\n, \nHan J\n, et al.\n Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway. JCI Insight 2024 9 e182352. (https:\/\/doi.org\/10.1172\/jci.insight.182352)"},{"key":"bib10","series-title":"Endocrinology","article-title":"Mechanisms in thyroid eye disease: the TSH receptor interacts directly with the IGF-1 receptor","volume":"166","author":"Latif R","year":"2025","unstructured":"Latif R\n, \nMezei M\n & \nDavies TF\n\n. Mechanisms in thyroid eye disease: the TSH receptor interacts directly with the IGF-1 receptor. Endocrinology 2025 166 bqaf009. (https:\/\/doi.org\/10.1210\/endocr\/bqaf009)"},{"key":"bib11","series-title":"Cytokine","article-title":"Role of IL-6 in the commitment of T cell subsets","volume":"146","author":"Korn T","year":"2021","unstructured":"Korn T\n & \nHiltensperger M\n\n. Role of IL-6 in the commitment of T cell subsets. Cytokine 2021 146 155654. (https:\/\/doi.org\/10.1016\/j.cyto.2021.155654)"},{"key":"bib12","series-title":"Front Ophthalmol","article-title":"The role of IL-6 in thyroid eye disease: an update on emerging treatments","volume":"5","author":"Murdock J","year":"2025","unstructured":"Murdock J\n, \nNguyen J\n, \nHurtgen BJ\n, et al.\n The role of IL-6 in thyroid eye disease: an update on emerging treatments. Front Ophthalmol 2025 5 1544436. (https:\/\/doi.org\/10.3389\/fopht.2025.1544436). Erratum in:Front Ophthalmol. 2025 5 1641164."},{"key":"bib13","series-title":"Expert Rev Ophthalmol","first-page":"227","article-title":"Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside","volume":"9","author":"Rajaii F","year":"2014","unstructured":"Rajaii F\n, \nMcCoy A\n & \nSmith T\n\n. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside. Expert Rev Ophthalmol 2014 9 227\u2013234. (https:\/\/doi.org\/10.1586\/17469899.2014.917960)"},{"key":"bib14","series-title":"Autoimmunity","first-page":"91","article-title":"High circulating IL-6 level in Graves\u2019 ophthalmopathy","volume":"25","author":"Molnar I","year":"1997","unstructured":"Molnar I\n & \nBalazs C\n\n. High circulating IL-6 level in Graves\u2019 ophthalmopathy. Autoimmunity 1997 25 91\u201396. (https:\/\/doi.org\/10.3109\/08916939708996275)"},{"key":"bib15","series-title":"Clin Exp Immunol","first-page":"453","article-title":"Both Th1- and Th2-derived cytokines in serum are elevated in Graves\u2019 ophthalmopathy","volume":"121","author":"Wakelkamp IM","year":"2001","unstructured":"Wakelkamp IM\n, \nGerding MN\n, \nVan Der Meer JW\n, et al.\n Both Th1- and Th2-derived cytokines in serum are elevated in Graves\u2019 ophthalmopathy. Clin Exp Immunol 2001 121 453\u2013457. (https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01335.x)"},{"key":"bib16","series-title":"Endocr Res","first-page":"89","article-title":"CD8 + CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves\u2019 orbitopathy and correlate with disease activity","volume":"37","author":"Slowik M","year":"2012","unstructured":"Slowik M\n, \nUrbaniak-Kujda D\n, \nBohdanowicz-Pawlak A\n, et al.\n CD8 + CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves\u2019 orbitopathy and correlate with disease activity. Endocr Res 2012 37 89\u201395. (https:\/\/doi.org\/10.3109\/07435800.2011.635622)"},{"key":"bib17","series-title":"J Clin Endocrinol Metab","first-page":"2976","article-title":"Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease","volume":"81","author":"Salvi M","year":"1996","unstructured":"Salvi M\n, \nGirasole G\n, \nPedrazzoni M\n, et al.\n Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease. J Clin Endocrinol Metab 1996 81 2976\u20132979. (https:\/\/doi.org\/10.1210\/jcem.81.8.8768861)"},{"key":"bib18","series-title":"Eur J Endocrinol","first-page":"197","article-title":"Serum concentrations of proinflammatory cytokines in Graves\u2019 disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking","volume":"143","author":"Salvi M","year":"2000","unstructured":"Salvi M\n, \nPedrazzoni M\n, \nGirasole G\n, et al.\n Serum concentrations of proinflammatory cytokines in Graves\u2019 disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000 143 197\u2013202. (https:\/\/doi.org\/10.1530\/eje.0.1430197)"},{"key":"bib19","series-title":"Thyroid","first-page":"59","article-title":"A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves\u2019 orbital preadipocyte fibroblasts","volume":"20","author":"Kumar S","year":"2010","unstructured":"Kumar S\n, \nSchiefer R\n, \nCoenen MJ\n, et al.\n A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves\u2019 orbital preadipocyte fibroblasts. Thyroid 2010 20 59\u201365. (https:\/\/doi.org\/10.1089\/thy.2009.0278)"},{"key":"bib20","series-title":"Sci Rep","article-title":"Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy","volume":"8","author":"Kishazi E","year":"2018","unstructured":"Kishazi E\n, \nDor M\n, \nEperon S\n, et al.\n Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy. Sci Rep 2018 8 10792. (https:\/\/doi.org\/10.1038\/s41598-018-29113-2)"},{"key":"bib21","series-title":"Thyroid","first-page":"338","article-title":"M1-like macrophages modulate fibrosis and inflammation of orbital fibroblasts in Graves\u2019 orbitopathy: potential relevance to soluble Interleukin-6 receptor","volume":"33","author":"Lu Y","year":"2023","unstructured":"Lu Y\n, \nWang Y\n, \nWang Y\n, et al.\n M1-like macrophages modulate fibrosis and inflammation of orbital fibroblasts in Graves\u2019 orbitopathy: potential relevance to soluble Interleukin-6 receptor. Thyroid 2023 33 338\u2013350. (https:\/\/doi.org\/10.1089\/thy.2022.0254)"},{"key":"bib22","series-title":"J Clin Endocrinol Metab","first-page":"1194","article-title":"Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy","volume":"85","author":"Hiromatsu Y","year":"2000","unstructured":"Hiromatsu Y\n, \nYang D\n, \nBednarczuk T\n, et al.\n Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000 85 1194\u20131199. (https:\/\/doi.org\/10.1210\/jcem.85.3.6433)"},{"key":"bib23","series-title":"Br J Ophthalmol","first-page":"639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits MP","year":"1989","unstructured":"Mourits MP\n, \nKoornneef L\n, \nWiersinga WM\n, et al.\n Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol 1989 73 639\u2013644. (https:\/\/doi.org\/10.1136\/bjo.73.8.639)"},{"key":"bib24","series-title":"Clin Endocrinol","first-page":"9","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourits MP","year":"1997","unstructured":"Mourits MP\n, \nPrummel MF\n, \nWiersinga WM\n, et al\n. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol 1997 47 9\u201314. (https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2331047.x). Erratum in: Clin Endocrinol 1997 47 632."},{"key":"bib25","series-title":"Am J Ophthalmol","first-page":"94","article-title":"Inter-observer variability of clinical activity score: assessments in patients with thyroid eye disease","volume":"252","author":"Perros P","year":"2023","unstructured":"Perros P\n, \n\u017darkovi\u0107 M\n, \nPearce SH\n, et al.\n Inter-observer variability of clinical activity score: assessments in patients with thyroid eye disease. Am J Ophthalmol 2023 252 94\u2013100. (https:\/\/doi.org\/10.1016\/j.ajo.2023.03.027)"},{"key":"bib26","series-title":"Horm Metab Res","first-page":"779","article-title":"Medical treatment of Graves\u2019 orbitopathy","volume":"47","author":"Salvi M","year":"2015","unstructured":"Salvi M\n & \nCampi I\n\n. Medical treatment of Graves\u2019 orbitopathy. Horm Metab Res 2015 47 779\u2013788. (https:\/\/doi.org\/10.1055\/s-0035-1554721)"},{"key":"bib27","series-title":"US Food & Drug Administration","article-title":"Drug trials snapshots: Summary report","year":"21 Feb 2021","unstructured":"Drug trials snapshots: Summary report. US Food & Drug Administration 21 Feb 2021. (https:\/\/www.fda.gov\/media\/145718\/download)"},{"key":"bib28","series-title":"Ophthalmology","first-page":"1092","article-title":"A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves\u2019 orbitopathy","volume":"120","author":"Campi I","year":"2013","unstructured":"Campi I\n, \nVannucchi GM\n, \nMinetti AM\n, et al.\n A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves\u2019 orbitopathy. Ophthalmology 2013 120 1092\u20131098. (https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.041)"},{"key":"bib29","series-title":"Sci Rep","article-title":"Measurement of proptosis using computed tomography based three-dimensional reconstruction software in patients with Graves\u2019 orbitopathy","volume":"10","author":"Huh J","year":"2020","unstructured":"Huh J\n, \nPark SJ\n & \nLee JK\n\n. Measurement of proptosis using computed tomography based three-dimensional reconstruction software in patients with Graves\u2019 orbitopathy. Sci Rep 2020 10 14554. (https:\/\/doi.org\/10.1038\/s41598-020-71098-4)"},{"key":"bib30","series-title":"Eur J Endocrinol","first-page":"273","article-title":"Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena L","year":"2008","unstructured":"Bartalena L\n, \nBaldeschi L\n, \nDickinson A\n, et al.\n Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008 158 273\u2013285. (https:\/\/doi.org\/10.1530\/eje-07-0666)"},{"key":"bib31","series-title":"Thyroid","first-page":"539","article-title":"The measurement of change in Graves\u2019 ophthalmopathy","volume":"8","author":"Gorman CA","year":"1998","unstructured":"Gorman CA\n\n. The measurement of change in Graves\u2019 ophthalmopathy. Thyroid 1998 8 539\u2013543. (https:\/\/doi.org\/10.1089\/thy.1998.8.539)"},{"key":"bib32","series-title":"Ophthalmology","first-page":"382","article-title":"Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study","volume":"119","author":"Dolman PJ","year":"2012","unstructured":"Dolman PJ\n, \nCahill K\n, \nCzyz CN\n, et al.\n Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. Ophthalmology 2012 119 382\u2013389. (https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.011)"},{"key":"bib33","series-title":"Thyroid","first-page":"280","article-title":"Quantification of global ocular motility impairment in Graves\u2019 orbitopathy by measuring eye muscle ductions","volume":"31","author":"Campi I","year":"2021","unstructured":"Campi I\n, \nCurr\u00f2 N\n, \nVannucchi G\n, et al.\n Quantification of global ocular motility impairment in Graves\u2019 orbitopathy by measuring eye muscle ductions. Thyroid 2021 31 280\u2013287. (https:\/\/doi.org\/10.1089\/thy.2020.0165)"},{"key":"bib34","series-title":"J Clin Endocrinol Metab","first-page":"4454","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena L","year":"2012","unstructured":"Bartalena L\n, \nKrassas GE\n, \nWiersinga W\n, et al.\n Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab 2012 97 4454\u20134463. (https:\/\/doi.org\/10.1210\/jc.2012-2389)"},{"key":"bib35","series-title":"Eur J Endocrinol","first-page":"R101","article-title":"Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy \u2013 lessons from randomized control trials","volume":"176","author":"Stan MN","year":"2017","unstructured":"Stan MN\n & \nSalvi M\n\n. Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy \u2013 lessons from randomized control trials. Eur J Endocrinol 2017 176 R101\u2013R109. (https:\/\/doi.org\/10.1530\/eje-16-0552)"},{"key":"bib36","series-title":"Lancet Diabetes Endocrinol","first-page":"733","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla G","year":"2021","unstructured":"Lanzolla G\n, \nSabini E\n, \nLeo M\n, et al.\n Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol 2021 9 733\u2013742. (https:\/\/doi.org\/10.1016\/s2213-8587(21)00238-2)"},{"key":"bib37","series-title":"Lancet Diabetes Endocrinol","first-page":"287","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly GJ","year":"2018","unstructured":"Kahaly GJ\n, \nRiedl M\n, \nK\u00f6nig J\n, et al.\n Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 2018 6 287\u2013298. (https:\/\/doi.org\/10.1016\/s2213-8587(18)30020-2)"},{"key":"bib38","series-title":"Clin Endocrinol","first-page":"391","article-title":"Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee CB","year":"2001","unstructured":"Terwee CB\n, \nDekker FW\n, \nMourits MP\n, et al.\n Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol 2001 54 391\u2013398. (https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01241.x)"},{"key":"bib39","series-title":"Eur J Endocrinol","first-page":"G43","article-title":"The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena L","year":"2021","unstructured":"Bartalena L\n, \nKahaly GJ\n, \nBaldeschi L\n, et al.\n The 2021 European group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 2021 185 G43\u2013G67. (https:\/\/doi.org\/10.1530\/eje-21-0479)"},{"key":"bib40","series-title":"Eur Thyroid J","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch HB","year":"2022","unstructured":"Burch HB\n, \nPerros P\n, \nBednarczuk T\n, et al.\n Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J 2022 11 e220189. (https:\/\/doi.org\/10.1530\/etj-22-0189)"},{"key":"bib41","series-title":"N Engl J Med","first-page":"1748","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith TJ","year":"2017","unstructured":"Smith TJ\n, \nKahaly GJ\n, \nEzra DG\n, et al.\n Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 2017 376 1748\u20131761. (https:\/\/doi.org\/10.1056\/nejmoa1614949)"},{"key":"bib42","series-title":"N Engl J Med","first-page":"341","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas RS","year":"2020","unstructured":"Douglas RS\n, \nKahaly GJ\n, \nPatel A\n, et al.\n Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020 382 341\u2013352. (https:\/\/doi.org\/10.1056\/nejmoa1910434)"},{"key":"bib43","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"162","article-title":"Treatment of active corticosteroid-resistant Graves\u2019 orbitopathy","volume":"30","author":"Perez-Moreiras JV","year":"2014","unstructured":"Perez-Moreiras JV\n, \nAlvarez-Lopez A\n & \nGomez EC\n\n. Treatment of active corticosteroid-resistant Graves\u2019 orbitopathy. Ophthalmic Plast Reconstr Surg 2014 30 162\u2013167. (https:\/\/doi.org\/10.1097\/iop.0000000000000037)"},{"key":"bib44","series-title":"Am J Ophthalmol","first-page":"181","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras JV","year":"2018","unstructured":"Perez-Moreiras JV\n, \nGomez-Reino JJ\n, \nManeiro JR\n, et al.\n Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 2018 195 181\u2013190. (https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038)"},{"key":"bib45","series-title":"J Clin Endocrinol Metab","first-page":"422","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi M","year":"2015","unstructured":"Salvi M\n, \nVannucchi G\n, \nCurr\u00f2 N\n, et al.\n Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015 100 422\u2013431. (https:\/\/doi.org\/10.1210\/jc.2014-3014)"},{"key":"bib46","series-title":"Thyroid","first-page":"821","article-title":"Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy","volume":"31","author":"Vannucchi G","year":"2021","unstructured":"Vannucchi G\n, \nCampi I\n, \nCovelli D\n, et al.\n Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid 2021 31 821\u2013828. (https:\/\/doi.org\/10.1089\/thy.2020.0269)"},{"key":"bib47","series-title":"Thyroid","first-page":"1181","article-title":"Future research in Graves\u2019 orbitopathy: from priority setting to trial design through patient and public involvement","volume":"25","author":"Perros P","year":"2015","unstructured":"Perros P\n, \nDayan CM\n, \nDickinson AJ\n, et al.\n Future research in Graves\u2019 orbitopathy: from priority setting to trial design through patient and public involvement. Thyroid 2015 25 1181\u20131184. (https:\/\/doi.org\/10.1089\/thy.2015.0222)"},{"key":"bib48","series-title":"Front Endocrinol","article-title":"How patients experience thyroid eye disease","volume":"14","author":"Smith TJ","year":"2023","unstructured":"Smith TJ\n, \nHeged\u00fcs L\n, \nLesser I\n, et al.\n How patients experience thyroid eye disease. Front Endocrinol 2023 14 1283374. (https:\/\/doi.org\/10.3389\/fendo.2023.1283374)"},{"key":"bib49","series-title":"Lancet Reg Health West Pac","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu Y","year":"2025","unstructured":"Hiromatsu Y\n, \nIshikawa E\n, \nKozaki A\n, et al.\n A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. Lancet Reg Health West Pac 2025 55 101464. (https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101464). Erratum in: Lancet Reg Health West Pac. 2025 60 101607."},{"key":"bib50","article-title":"First treatment against severe thyroid eye disease","author":"European Medicines Agency","year":"25 Apr 2025","unstructured":"European Medicines Agency\n. First treatment against severe thyroid eye disease. 25 Apr 2025. (https:\/\/www.ema.europa.eu\/en\/news\/first-treatment-against-severe-thyroid-eye-disease)"},{"key":"bib51","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"583","article-title":"Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population","volume":"37","author":"Diniz SB","year":"2021","unstructured":"Diniz SB\n, \nCohen LM\n, \nRoelofs KA\n, et al.\n Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg 2021 37 583\u2013591. (https:\/\/doi.org\/10.1097\/iop.0000000000001959)"},{"key":"bib52","series-title":"Thyroid","first-page":"1202","article-title":"Teprotumumab treatment in patients with steroid and surgery-resistant dysthyroid optic neuropathy: a case series","volume":"35","author":"Carretti AL","year":"2025","unstructured":"Carretti AL\n, \nKielwasser G\n, \nBorson-Chazot F\n, et al.\n Teprotumumab treatment in patients with steroid and surgery-resistant dysthyroid optic neuropathy: a case series. Thyroid 2025 35 1202\u20131207. (https:\/\/doi.org\/10.1177\/10507256251372194)"},{"key":"bib53","series-title":"J Neuro Ophthalmol","first-page":"74","article-title":"Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy","volume":"44","author":"Tamhankar MA","year":"2024","unstructured":"Tamhankar MA\n, \nPradeep T\n, \nChen Y\n, et al.\n Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy. J Neuro Ophthalmol 2024 44 74\u201379. (https:\/\/doi.org\/10.1097\/wno.0000000000001994)"},{"key":"bib54","series-title":"Ophthalmology","first-page":"438","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas RS","year":"2022","unstructured":"Douglas RS\n, \nKahaly GJ\n, \nUgradar S\n, et al.\n Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology 2022 129 438\u2013449. (https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017)"},{"key":"bib55","series-title":"J Clin Endocrinol Metab","first-page":"25","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas RS","year":"2023","unstructured":"Douglas RS\n, \nCouch S\n, \nWester ST\n, et al.\n Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab 2023 109 25\u201335. (https:\/\/doi.org\/10.1210\/clinem\/dgad637)"},{"key":"bib56","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"187","article-title":"Proptosis regression after teprotumumab treatment for thyroid eye disease","volume":"40","author":"Rosenblatt TR","year":"2024","unstructured":"Rosenblatt TR\n, \nChiou CA\n, \nYoon MK\n, et al.\n Proptosis regression after teprotumumab treatment for thyroid eye disease. Ophthalmic Plast Reconstr Surg 2024 40 187\u2013191. (https:\/\/doi.org\/10.1097\/iop.0000000000002531)"},{"key":"bib57","series-title":"Am J Ophthalmol","first-page":"152","article-title":"Reactivation after teprotumumab treatment for active thyroid eye disease","volume":"263","author":"Hwang CJ","year":"2024","unstructured":"Hwang CJ\n, \nRebollo NP\n, \nMechels KB\n, et al.\n Reactivation after teprotumumab treatment for active thyroid eye disease. Am J Ophthalmol 2024 263 152\u2013159. (https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001)"},{"key":"bib58","series-title":"Ophthalmology","first-page":"815","article-title":"Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials","volume":"131","author":"Smith TJ","year":"2024","unstructured":"Smith TJ\n, \nCavida D\n, \nHsu K\n, et al.\n Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials. Ophthalmology 2024 131 815\u2013826. (https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.023)"},{"key":"bib59","series-title":"Ophthalmology","first-page":"30","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen JA","year":"2024","unstructured":"Keen JA\n, \nCorrea T\n, \nPham C\n, et al.\n Frequency and patterns of hearing dysfunction in patients treated with teprotumumab. Ophthalmology 2024 131 30\u201336. (https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.001)"},{"key":"bib60","series-title":"J Clin Endocrinol Metab","first-page":"811","article-title":"Assessment of hearing dysfunction in patients with Graves\u2019 disease and thyroid eye disease without or with teprotumumab","volume":"110","author":"Smith TJ","year":"2025","unstructured":"Smith TJ\n, \nHolt RJ\n, \nFu Q\n, et al.\n Assessment of hearing dysfunction in patients with Graves\u2019 disease and thyroid eye disease without or with teprotumumab. J Clin Endocrinol Metab 2025 110 811\u2013819. (https:\/\/doi.org\/10.1210\/clinem\/dgae560)"},{"key":"bib61","series-title":"JAMA Ophthalmol","article-title":"IGF-1R inhibitor IBI311 for the treatment of active thyroid eye disease in Chinese patients: the RESTORE-1 randomized clinical trial","volume":"9","author":"Zhang H","year":"2025","unstructured":"Zhang H\n, \nSun J\n, \nLi Y\n, et al.\n IGF-1R inhibitor IBI311 for the treatment of active thyroid eye disease in Chinese patients: the RESTORE-1 randomized clinical trial. JAMA Ophthalmol 2025 9 e253350. (https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.3350)"},{"key":"bib62","series-title":"Front Endocrinol","article-title":"Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease","volume":"14","author":"Gulbins A","year":"2023","unstructured":"Gulbins A\n, \nHorstmann M\n, \nDaser A\n, et al.\n Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Front Endocrinol 2023 14 1211473. (https:\/\/doi.org\/10.3389\/fendo.2023.1211473)"},{"key":"bib63","series-title":"BioDrugs","first-page":"61","article-title":"Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned?","volume":"38","author":"Avci AB","year":"2024","unstructured":"Avci AB\n, \nFeist E\n & \nBurmester GR\n\n. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned? BioDrugs 2024 38 61\u201371. (https:\/\/doi.org\/10.1007\/s40259-023-00634-1)"},{"key":"bib64","series-title":"RMD Open","article-title":"A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases","volume":"8","author":"Kastrati K","year":"2022","unstructured":"Kastrati K\n, \nAletaha D\n, \nBurmester GR\n, et al.\n A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 2022 8 e002359. (https:\/\/doi.org\/10.1136\/rmdopen-2022-002359)"},{"key":"bib65","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"367","article-title":"Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review","volume":"40","author":"Duarte AF","year":"2024","unstructured":"Duarte AF\n, \nXavier NF\n, \nSales Sanz M\n, et al.\n Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review. Ophthalmic Plast Reconstr Surg 2024 40 367\u2013373. (https:\/\/doi.org\/10.1097\/iop.0000000000002573)"},{"key":"bib66","series-title":"Clin Endocrinol","first-page":"363","article-title":"Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab","volume":"97","author":"Moi L","year":"2022","unstructured":"Moi L\n, \nHamedani M\n & \nRibi C\n\n. Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab. Clin Endocrinol 2022 97 363\u2013370. (https:\/\/doi.org\/10.1111\/cen.14655)"},{"key":"bib67","series-title":"Int Ophthalmol","first-page":"179","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study","volume":"44","author":"Lee C","year":"2024","unstructured":"Lee C\n, \nPark JW\n, \nKim YD\n, et al.\n Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study. Int Ophthalmol 2024 44 179. (https:\/\/doi.org\/10.1007\/s10792-024-03117-6)"},{"key":"bib68","series-title":"J Clin Endocrinol Metab","first-page":"e886","article-title":"The efficacy and safety of intravenous tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and single-arm meta-analysis","volume":"110","author":"Sun A","year":"2025","unstructured":"Sun A\n, \nWang X\n, \nQu J\n, et al.\n The efficacy and safety of intravenous tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and single-arm meta-analysis. J Clin Endocrinol Metab 2025 110 e886\u2013e896. (https:\/\/doi.org\/10.1210\/clinem\/dgae711)"},{"key":"bib69","series-title":"Front Endocrinol","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study","volume":"14","author":"Boutzios G","year":"2023","unstructured":"Boutzios G\n, \nChatzi S\n, \nGoules AV\n, et al.\n Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study. Front Endocrinol 2023 14 1186105. (https:\/\/doi.org\/10.3389\/fendo.2023.1186105)"},{"key":"bib70","series-title":"Taiwan J Ophthalmol","first-page":"39","article-title":"Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers","volume":"12","author":"Stevens SM","year":"2022","unstructured":"Stevens SM\n, \nPirakitikulr N\n & \nLee BW\n\n. Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers. Taiwan J Ophthalmol 2022 12 39\u201343. (https:\/\/doi.org\/10.4103\/tjo.tjo_59_21)"},{"key":"bib71","series-title":"Ophthalmic Plast Reconstr Surg","first-page":"e64","article-title":"Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery","volume":"35","author":"Copperman T","year":"2019","unstructured":"Copperman T\n, \nIdowu OO\n, \nKersten RC\n, et al.\n Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast Reconstr Surg 2019 35 e64\u2013e66. (https:\/\/doi.org\/10.1097\/iop.0000000000001346)"},{"key":"bib72","series-title":"Lancet Neurol","first-page":"402","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee A","year":"2020","unstructured":"Traboulsee A\n, \nGreenberg BM\n, \nBennett JL\n, et al.\n Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020 19 402\u2013412. (https:\/\/doi.org\/10.1016\/s1474-4422(20)30078-8)"},{"key":"bib73","series-title":"N Engl J Med","first-page":"2114","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura T","year":"2019","unstructured":"Yamamura T\n, \nKleiter I\n, \nFujihara K\n, et al.\n Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019 381 2114\u20132124. (https:\/\/doi.org\/10.1056\/nejmoa1901747)"},{"key":"bib74","series-title":"Mol Immunol","first-page":"131","article-title":"Targeting FcRn for the modulation of antibody dynamics","volume":"67","author":"Ward ES","year":"2015","unstructured":"Ward ES\n, \nDevanaboyina SC\n & \nOber RJ\n\n. Targeting FcRn for the modulation of antibody dynamics. Mol Immunol 2015 67 131\u2013141. (https:\/\/doi.org\/10.1016\/j.molimm.2015.02.007)"},{"key":"bib75","series-title":"Immunol Rev","first-page":"253","article-title":"The multiple facets of FcRn in immunity","volume":"268","author":"Stapleton NM","year":"2015","unstructured":"Stapleton NM\n, \nEinarsd\u00f3ttir HK\n, \nStemerding AM\n, et al.\n The multiple facets of FcRn in immunity. Immunol Rev 2015 268 253\u2013268. (https:\/\/doi.org\/10.1111\/imr.12331)"},{"key":"bib76","series-title":"Adv Drug Deliver Rev","first-page":"109","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky JT","year":"2015","unstructured":"Sockolosky JT\n & \nSzoka FC\n\n. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliver Rev 2015 91 109\u2013124. (https:\/\/doi.org\/10.1016\/j.addr.2015.02.005)"},{"key":"bib77","series-title":"J Clin Endocrinol Metab","first-page":"3122","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly GJ","year":"2023","unstructured":"Kahaly GJ\n, \nDolman PJ\n, \nWolf J\n, et al.\n Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab 2023 108 3122\u20133134. (https:\/\/doi.org\/10.1210\/clinem\/dgad381)"},{"key":"bib78","series-title":"J Endocr Soc","article-title":"OR31-08 the FcRn inhibitor batoclimab rapidly normalizes thyroid function and improves clinical outcomes in Graves\u2019 disease","volume":"9","author":"Kahaly GJ","year":"2025","unstructured":"Kahaly GJ\n, \nWolf J\n, \nGanz AL\n, et al.\n OR31-08 the FcRn inhibitor batoclimab rapidly normalizes thyroid function and improves clinical outcomes in Graves\u2019 disease. J Endocr Soc 2025 9 bvaf1492241. (https:\/\/doi.org\/10.1210\/jendso\/bvaf149.2241)"},{"key":"bib79","series-title":"J Clin Endocrinol Metab","article-title":"Secukinumab in moderate-to-severe Graves\u2019 orbitopathy: a randomized, double-blind, placebo-controlled, multicenter study","volume":"9","author":"Wolf J","year":"2025","unstructured":"Wolf J\n, \nLorenz K\n, \nOthman AE\n, et al.\n Secukinumab in moderate-to-severe Graves\u2019 orbitopathy: a randomized, double-blind, placebo-controlled, multicenter study. J Clin Endocrinol Metab 2025 9 dgaf655. (https:\/\/doi.org\/10.1210\/clinem\/dgaf655)"},{"key":"bib80","series-title":"Nature","first-page":"1282","article-title":"Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43","volume":"461","author":"Maslowski KM","year":"2009","unstructured":"Maslowski KM\n, \nVieira AT\n, \nNg A\n, et al.\n Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009 461 1282\u20131286. (https:\/\/doi.org\/10.1038\/nature08530)"},{"key":"bib81","series-title":"Compar Med","first-page":"336","article-title":"Variation in the gut microbiota of laboratory mice is related to both genetic and environmental factors","volume":"60","author":"Hufeldt MR","year":"2010","unstructured":"Hufeldt MR\n, \nNielsen DS\n, \nVogensen FK\n, et al.\n Variation in the gut microbiota of laboratory mice is related to both genetic and environmental factors. Compar Med 2010 60 336\u2013347."},{"key":"bib82","series-title":"Microbiome","first-page":"97","article-title":"Gut microbiota in experimental murine model of Graves\u2019 orbitopathy established in different environments may modulate clinical presentation of disease","volume":"6","author":"Masetti G","year":"2018","unstructured":"Masetti G\n, \nMoshkelgosha S\n, \nK\u00f6hling HL\n, et al.\n Gut microbiota in experimental murine model of Graves\u2019 orbitopathy established in different environments may modulate clinical presentation of disease. Microbiome 2018 6 97. (https:\/\/doi.org\/10.1186\/s40168-018-0478-4)"},{"key":"bib83","series-title":"Microbiome","first-page":"45","article-title":"Modulating gut microbiota in a mouse model of Graves\u2019 orbitopathy and its impact on induced disease","volume":"9","author":"Moshkelgosha S","year":"2021","unstructured":"Moshkelgosha S\n, \nVerhasselt HL\n, \nMasetti G\n, et al.\n Modulating gut microbiota in a mouse model of Graves\u2019 orbitopathy and its impact on induced disease. Microbiome 2021 9 45. (https:\/\/doi.org\/10.1186\/s40168-020-00952-4)"},{"key":"bib84","series-title":"Front Endocrinol","article-title":"Association between gut microbiota and autoimmune thyroid disease: a systematic review and meta-analysis","volume":"12","author":"Gong B","year":"2021","unstructured":"Gong B\n, \nWang C\n, \nMeng F\n, et al.\n Association between gut microbiota and autoimmune thyroid disease: a systematic review and meta-analysis. Front Endocrinol 2021 12 774362. (https:\/\/doi.org\/10.3389\/fendo.2021.774362)"},{"key":"bib85","series-title":"Nat Rev Endocrinol","first-page":"511","article-title":"The relationship between the gut microbiota and thyroid disorders","volume":"20","author":"Ludgate ME","year":"2024","unstructured":"Ludgate ME\n, \nMasetti G\n & \nSoares P\n\n. The relationship between the gut microbiota and thyroid disorders. Nat Rev Endocrinol 2024 20 511\u2013525. (https:\/\/doi.org\/10.1038\/s41574-024-01003-w)"},{"key":"bib86","series-title":"J Clin Endocrinol Metab","first-page":"2065","article-title":"Gut microbiome associated with Graves disease and Graves orbitopathy: the INDIGO multicenter European Study","volume":"108","author":"Biscarini F","year":"2023","unstructured":"Biscarini F\n, \nMasetti G\n, \nMuller I\n, et al.\n Gut microbiome associated with Graves disease and Graves orbitopathy: the INDIGO multicenter European Study. J Clin Endocrinol Metab 2023 108 2065\u20132077. (https:\/\/doi.org\/10.1210\/clinem\/dgad030). Erratum in: J Clin Endocrinol Metab. 2024 109 e880."},{"key":"bib87","series-title":"Endocrine","first-page":"689","article-title":"Large language models: unlocking new potential in patient education for thyroid eye disease","volume":"90","author":"Gao Y","year":"2025","unstructured":"Gao Y\n, \nXu Q\n, \nZhang O\n, et al.\n Large language models: unlocking new potential in patient education for thyroid eye disease. Endocrine 2025 90 689\u2013698. (https:\/\/doi.org\/10.1007\/s12020-025-04339-z)"},{"key":"bib88","series-title":"Front Endocrinol","article-title":"Application of artificial intelligence in the assessment of thyroid eye disease (TED) \u2013 a scoping review","volume":"14","author":"Chng CL","year":"2023","unstructured":"Chng CL\n, \nZheng K\n, \nKwee AK\n, et al.\n Application of artificial intelligence in the assessment of thyroid eye disease (TED) \u2013 a scoping review. Front Endocrinol 2023 14 1300196. (https:\/\/doi.org\/10.3389\/fendo.2023.1300196)"},{"key":"bib89","series-title":"Ophthalmology","first-page":"1703","article-title":"Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network","volume":"109","author":"Salvi M","year":"2002","unstructured":"Salvi M\n, \nDazzi D\n, \nPellistri I\n, et al.\n Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network. Ophthalmology 2002 109 1703\u20131708. (https:\/\/doi.org\/10.1016\/s0161-6420(02)01127-2)"},{"key":"bib90","series-title":"Surv Ophthalmol","first-page":"142","article-title":"Artificial intelligence in thyroid eye disease imaging: a systematic review","volume":"71","author":"Zhang H","year":"2026","unstructured":"Zhang H\n, \nLi Z\n, \nChan HC\n, et al.\n Artificial intelligence in thyroid eye disease imaging: a systematic review. Surv Ophthalmol 2026 71 142\u2013157. (https:\/\/doi.org\/10.1016\/j.survophthal.2025.07.008)"},{"key":"bib91","series-title":"Ophthalmol Sci","article-title":"Deep learning-driven exophthalmometry through facial photographs in thyroid eye disease","volume":"5","author":"Park J","year":"2025","unstructured":"Park J\n, \nYoon JS\n, \nKim N\n, et al.\n Deep learning-driven exophthalmometry through facial photographs in thyroid eye disease. Ophthalmol Sci 2025 5 100791. (https:\/\/doi.org\/10.1016\/j.xops.2025.100791)"},{"key":"bib92","series-title":"BMJ Open Ophthalmol","article-title":"AI-based assessment of clinical activity score and detection of active thyroid eye disease using facial images: validation of Glandy CAS","volume":"10","author":"Shin K","year":"2025","unstructured":"Shin K\n, \nYoon JS\n, \nKim J\n, et al.\n AI-based assessment of clinical activity score and detection of active thyroid eye disease using facial images: validation of Glandy CAS. BMJ Open Ophthalmol 2025 10 e002264. (https:\/\/doi.org\/10.1136\/bmjophth-2025-002264)"},{"key":"bib93","series-title":"BMC Ophthalmol","first-page":"162","article-title":"Comparative analysis of deep learning architectures for thyroid eye disease detection using facial photographs","volume":"25","author":"Aghajani A","year":"2025","unstructured":"Aghajani A\n, \nRajabi MT\n, \nRafizadeh SM\n, et al.\n Comparative analysis of deep learning architectures for thyroid eye disease detection using facial photographs. BMC Ophthalmol 2025 25 162. (https:\/\/doi.org\/10.1186\/s12886-025-03988-y)"},{"key":"bib94","series-title":"Thyroid","first-page":"744","article-title":"A preliminary evaluation of the diagnostic performance of a smartphone-based machine learning-assisted system for evaluation of clinical activity score in digital images of thyroid-associated orbitopathy","volume":"34","author":"Shin K","year":"2024","unstructured":"Shin K\n, \nChoung H\n, \nLee MJ\n, et al.\n A preliminary evaluation of the diagnostic performance of a smartphone-based machine learning-assisted system for evaluation of clinical activity score in digital images of thyroid-associated orbitopathy. Thyroid 2024 34 744\u2013752. (https:\/\/doi.org\/10.1089\/thy.2023.0621)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/15\/1\/ETJ-25-0363.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/15\/1\/ETJ-25-0363.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/15\/1\/ETJ-25-0363.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:58:50Z","timestamp":1772031530000},"score":1,"resource":{"primary":{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/15\/1\/ETJ-25-0363.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":188,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0363","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}